Cargando…

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

BACKGROUND: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the effects of cardiovascular function on SGLT2 inhibitors c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sook Jung, Lee, Kook Hyung, Oh, Hyun Geong, Seo, Hye Ji, Jeong, Soo Jin, Kim, Chong Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939702/ https://www.ncbi.nlm.nih.gov/pubmed/31909368 http://dx.doi.org/10.7570/jomes.2019.28.4.254

Ejemplares similares

Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
por: Shaheer, Abid, et al.
Publicado: (2021)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)

Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
por: Min, Se Hee, et al.
Publicado: (2018)

Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
por: Zhou, Jiandong, et al.
Publicado: (2022)

Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
por: Chung, Cheuk To, et al.
Publicado: (2023)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Ling, Ann Wan-Chin, et al.
Publicado: (2020)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
por: Foresta, Andreana, et al.
Publicado: (2023)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
por: Mui, Jonathan V., et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
por: Yassin, Sayf A, et al.
Publicado: (2017)

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
por: Ng, Pauline Yeung, et al.
Publicado: (2023)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Lee, Hsin-Fu, et al.
Publicado: (2023)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2017)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Bae, Jae Hyun, et al.
Publicado: (2021)

Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
por: Sharma, M D
Publicado: (2015)

A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin
por: Huang, Chung-Huei, et al.
Publicado: (2018)

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
por: Sugawara, Masahiro, et al.
Publicado: (2023)

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
por: Lee, Dong-Hwa, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
por: Mui, Jonathan V., et al.
Publicado: (2021)

Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
por: Jeong, Han Eol, et al.
Publicado: (2023)

Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
por: Kashiwagi, Atsunori, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
por: Jung, Chan-Hee
Publicado: (2021)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh, Hala, et al.
Publicado: (2017)

Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
por: Han, Seung Jin, et al.
Publicado: (2020)

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
por: Lee, Sharen, et al.
Publicado: (2022)

Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong
por: Au, Philip C. M., et al.
Publicado: (2023)

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan
por: Kashiwagi, Atsunori, et al.
Publicado: (2022)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
por: Seo, Ji A
Publicado: (2019)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5lp78ik4qpmsbjgi2ffcpb06s